A new era for sunscreen?
Plus: NAD+ and retinal health, GLP-1s, labor timing, and brain plasticity.
Elysium Abstract <[email protected]>
Share
Elysium Health announces the FDA's approval of a new sunscreen active ingredient, bemotrizinol, for the first time in decades. The company offers expert commentary from Dr. Richard Granstein on the benefits of bemotrizinol, which provides broad-spectrum protection against UVA and UVB rays. Elysium Health also highlights other research topics in its July edition of The Abstract.
What the raw message shows
From the headers
- Sent with
-
Klaviyo See it in the headers
In the HTML
- Built with
- Dark-mode styles
Across Elysium Health's email
- Sends
- About 2 a week
- DMARC
-
Enforced, quarantine
Mail failing authentication goes to spam.
The copy
551 words · about 2 min to read · 1 button
Thanks for reading The Abstract. This month’s edition is 1,083 words, about a 4-minute read.
Is there a topic that you’d like to see more of in The Abstract? Drop us a line at [email protected]. Want to get The Abstract in your inbox? Sign up here.
The Abstract
Summer is peak sunscreen season, and this month brought a notable update: The FDA approved a new sunscreen active ingredient for the first time in decades. We offer expert commentary from Dr. Richard Granstein, a world-renowned leader in the field of dermatology and member of the Elysium Scientific Advisory Board. Also in the July edition of The Abstract: new research on NAD+ and retinal cell resilience, placental metabolism and the timing of labor, whether GLP-1 medications may have a role in longevity, and how brain health can improve across adulthood.
FDA approves a new sunscreen ingredient for the first time in decades
For the first time since the late 1990s, the FDA has added a new active ingredient to the list of permitted over-the-counter sunscreen ingredients. Bemotrizinol (BEMT), already used in Europe and other markets, protects against both UVA and UVB rays and has low levels of absorption through the skin. The FDA considers it generally recognized as safe and effective for adults and children 6 months and older, opening the door to more modern sunscreen formulations in the U.S. market. The first sunscreen products with bemotrizinol are expected to be available in the U.S. in fall 2026.
The Expert’s Take:
“Bemotrizinol provides broad-spectrum protection against both UVB and UVA radiation. UVB is the primary cause of sunburn and a major contributor to skin cancer and skin aging, while UVA plays a significant role in photoaging and also contributes to skin cancer. Compared with many currently used sunscreen ingredients, bemotrizinol offers several important advantages. It is highly photostable, maintaining its effectiveness during prolonged sun exposure, whereas many chemical UV filters degrade over time and may form byproducts that can irritate the skin.
Another key advantage is that bemotrizinol is very poorly absorbed through the skin. In contrast, several commonly used chemical sunscreen ingredients can be detected in the bloodstream after application, raising ongoing questions about their potential biological effects, including possible hormone-disrupting activity. Mineral sunscreens avoid this concern but often leave a white cast that many people find cosmetically undesirable. As a chemical UV filter, bemotrizinol provides effective protection without this drawback.
Skin cancer is the most common group of human malignancies and remains a major cause of illness, healthcare costs, and, particularly in the case of melanoma, death. The approval of bemotrizinol represents an important advance for public health in the United States.”
Richard Granstein, M.D.
George W. Hambrick, Jr. Professor and Chair of the Israel Englander Department of Dermatology, Weill Cornell Medicine, and member of the Elysium Scientific Advisory Board*
Button Read more
Your summer skin routine, from within | Mosaic helps counter internal and external stressors that drive visible skin aging—with clinically proven carotenoids and hyaluronic acid to improve: | Shop Mosaic
THIS MONTH
What We’re Reading
These are third-party articles about science that we find interesting but have no relationship to Elysium or any of our products. Elysium’s products are not intended to screen, diagnose, treat, cure, or prevent any disease.
Your brain may be more adaptable than you think
The words as text: what a screen reader can follow, and all there is when images don't load.
What the headers say
Read from the message's own headers, as it arrived.
- Came from
-
o1280.shared.klaviyomail.com
· 167.89.72.22
Klaviyo's sending servers
- SPF
- Pass for send.elysiumhealth.com
- DKIM
-
- Pass signed by elysiumhealth.com
- DMARC
-
Pass for elysiumhealth.com
Policy: quarantine
- Unsubscribe
-
One-click
Meets the Gmail and Yahoo rule for bulk senders.
- Complaints
- No feedback-loop header
Show all 21 headers Hide the headers
As received, minus the delivery side: the archive's own addresses show as [recipient], its mail servers as [receiver], signatures are left out and unsubscribe links trimmed to their host.
Route
- Received Identifies Klaviyo
- from o1280.shared.klaviyomail.com (167.89.72.22) by [receiver] (cloudflare) id hDHbcTqIxh3o for <[recipient]>; Sun, 19 Jul 2026 12:00:38 +0000
- Received
- by recvd-7687dff5c-fzv7z with SMTP id recvd-7687dff5c-fzv7z-1-6A5CBC65-333 2026-07-19 12:00:37.815716492 +0000 UTC m=+825530.878990771
- Received
- from MjAwMDcxNDM (unknown) by geopod-ismtpd-21 (SG) with HTTP id 4e101m8yT3u59FyNNTjVsw Sun, 19 Jul 2026 12:00:37.809 +0000 (UTC)
Authentication
- Received-SPF Authentication result
- pass ([receiver]: domain of [recipient]@send.elysiumhealth.com designates 167.89.72.22 as permitted sender) receiver=[receiver]; client-ip=167.89.72.22; envelope-from="[recipient]@send.elysiumhealth.com"; helo=o1280.shared.klaviyomail.com;
- Authentication-Results Authentication result
- [receiver]; dkim=pass header.d=elysiumhealth.com header.s=kl2 header.b=nTYI/ngW; dmarc=pass header.from=elysiumhealth.com policy.dmarc=quarantine; spf=none ([receiver]: no SPF records found for [email protected]) smtp.helo=o1280.shared.klaviyomail.com; spf=pass ([receiver]: domain of [recipient]@send.elysiumhealth.com designates 167.89.72.22 as permitted sender) smtp.mailfrom=[recipient]@send.elysiumhealth.com; arc=none smtp.remote-ip=167.89.72.22
Platform
- X-Kmail-Account
- R8xQKv
- X-Kmail-Message
- 01KXRVGVXWR1325X9KRPPAJNFX
- X-Kmail-Ops
- 01KX28G5HSKQA9CNV085MJW4AC
- X-SG-EID
- u001.Xv32TvI6iuV+tZ4vlqHO3HOP0TVxYBknYAX4/Mby5Th0PYwVlaUDVZEfaaXcBa1/i/If+231cWgIYCosFVQxSCNYYl6BGiqU2eWIsl3cko4bWKxUBEmWOc2WZZ3sjdjeV9puYMSnEqKan6JhUo7BAfwyTiG+NRCgYo/z/xNNhqzcu38WfKaRnzffTT8weN3UbZYqn7MOhmRF0tdhxSYqzaYyCbmJI2OmDrbxNikQO/+gkmsx9ufrv5+OyPVBXiBY
- X-SG-ID
- u001.SdBcvi+Evd/bQef8eZF3BiU3Zi1S53GtqGa3TWBmqe75yn5aYrkvkfG+ZGKrHRvqHEqNnYhXzKEMbIPUuNbUdfpjphyJI24ahdp5cMyD+gtd10HMsYQGG+9KCgoFZ++5usaE1rO9s7wHD0xpqN9fPZSfd0raNCPr6x9v52fVvY9diIXzZKlpjDU7+a0x/IpdEM0gUz+nwIauzjD2pB+V3roY+TT8pUndtRVZmRcv6ATHsaGWdjGZViuJP7NQj4fA3hMt73HOZeRrK2zqh3LVVDzTo5+WdoIXzpTPUT2KFVDBA6KSytUIoyenQcZRhLh8azHd+o/TMqkk88BOkCk91kQGQp8M6erEge1TVf1RbwkpG1dP27oeHFPbHczGbNQG
- X-Entity-ID
- u001.lP8bpbcNOc7n5/pI/ei+9g==
Unsubscribe and feedback
- List-Unsubscribe
- <https://manage.kmail-lists.com/…>
- List-Unsubscribe-Post
- List-Unsubscribe=One-Click
- X-Report-Abuse
- Please report any spam or abuse to: [email protected]
Message
- Content-Type
- multipart/alternative; boundary=693fbe31292dca7c51c032aa02c8a3773e1ac71536a40335569f71ad00c8
- Date
- Sun, 19 Jul 2026 12:00:38 +0000 (UTC)
- From
- Elysium Abstract <[email protected]>
- Mime-Version
- 1.0
- Message-ID
- <4e101m8yT3u59FyNNTjVsw@geopod-ismtpd-21>
- Subject
- A new era for sunscreen?
- Reply-To
- [email protected]
More from Elysium Health
All 32 emailsSimilar campaigns from other brands
Different brands running the same play. Compare any of them side by side.
Archived for reference and commentary. Elysium Health, its logos and content are the property of their respective owners; Inbox Archive claims no affiliation and has disabled all links. If you own this content and would like it removed, get in touch.